In our study, six validated targets of METTL3 were observed to be associated with the occurrence and survival of multiple cancers including glioma, which is similar to previous reports that NASP, TIMP1, U2AF2, and VEGFA were upregulated in other cancers, and TIMP1 had a broad correlation with the progression or poor prognosis of multiple cancers, while PHLPP2 was downregulated in colorectal cancer and colon cancer (Ali-Fehmi et al., 2010; Guo et al., 2015; Jackson et al., 2017; Cao et al., 2019; Li J. et al., 2019; Wu et al., 2019, 2020; Kong et al., 2020; Supplementary Table S11). The gene discussed is METTL3; the disease is cancer.